echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Takeda's treatment drug Feizeyou for acute hereditary angioedema episodes is approved to protect the lives of Chinese HAE patients

    Takeda's treatment drug Feizeyou for acute hereditary angioedema episodes is approved to protect the lives of Chinese HAE patients

    • Last Update: 2021-04-18
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    April 8, 2021, Shanghai — Takeda China announced that Feizeyou® (icatibant acetate injection) has been officially approved by the National Medical Products Administration for the treatment of heredity in adults, adolescents and children ≥2 years of age Acute onset of angioedema (HAE).


    Bradykinin B2 receptor antagonist is an on-demand treatment plan recommended by major international HAE diagnosis and treatment guidelines during acute attacks.


    Hereditary angioedema is a rare autosomal dominant genetic disease1.


    "Because of the lack of targeted treatment drugs for the acute stage of HAE in China, we can only rely on the infusion of freeze-dried fresh plasma to resolve the edema.


    Professor Zhi Yuxiang, Department of Allergy, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences

    A number of phase III clinical studies and a real-world observational study after the market have confirmed that Feizeyou® (icatibant acetate injection) has rapid onset and alleviation of edema in various parts of HAE, and its tolerability and safety are also high.


    “Thank you very much for the priority review and approval of relevant government departments, so that Takeda can introduce two innovative treatment products for Chinese HAE patients in just one year, to meet the urgent needs of patients for preventive treatment and emergency treatment, and to protect the health of patients throughout the process.


    Mr.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.